StockData
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. (TRVI) stock

TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$13.51+0.00 (0.00%)

Close on Nov 18, 2026Market cap $1.92BP/E –Yield –

Trevi Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Trevi Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$59.56M. For fiscal 2025 it was -$49.33M. The highest annual figure on record is -$18.41M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$49.33M–
FY2024Dec 31, 2024-$51.52M–
FY2023Dec 31, 2023-$33.92M–
FY2022Dec 31, 2022-$29.91M–
FY2021Dec 31, 2021-$32.48M–
FY2020Dec 31, 2020-$32.49M–
FY2019Dec 31, 2019-$26.65M–
FY2018Dec 31, 2018-$18.41M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$20.51M–
Q1 FY2026Mar 31, 2026-$14.91M–
Q4 FY2025Dec 31, 2025-$10.22M–
Q3 FY2025Sep 30, 2025-$13.92M–
Q2 FY2025Jun 30, 2025-$13.72M–
Q1 FY2025Mar 31, 2025-$11.47M–
Q4 FY2024Dec 31, 2024-$12.24M–
Q3 FY2024Sep 30, 2024-$14.09M–
Q2 FY2024Jun 30, 2024-$13.29M–
Q1 FY2024Mar 31, 2024-$11.91M–
Q4 FY2023Dec 31, 2023-$8.93M–
Q3 FY2023Sep 30, 2023-$9.05M–
Q2 FY2023Jun 30, 2023-$8.38M–
Q1 FY2023Mar 31, 2023-$7.56M–
Q4 FY2022Dec 31, 2022-$6.66M–
Q3 FY2022Sep 30, 2022-$8.41M–
Q2 FY2022Jun 30, 2022-$7.82M–
Q1 FY2022Mar 31, 2022-$7.03M–
Q4 FY2021Dec 31, 2021-$8.27M–
Q3 FY2021Sep 30, 2021-$6.95M–
Q2 FY2021Jun 30, 2021-$9.17M–
Q1 FY2021Mar 31, 2021-$8.09M–
Q4 FY2020Dec 31, 2020-$9.19M–
Q3 FY2020Sep 30, 2020-$7.24M–
Q2 FY2020Jun 30, 2020-$7.41M–
Q1 FY2020Mar 31, 2020-$8.64M–
Q4 FY2019Dec 31, 2019-$6.77M–
Q3 FY2019Sep 30, 2019-$7.65M–
Q2 FY2019Jun 30, 2019-$7.42M–
Q1 FY2019Mar 31, 2019-$4.81M–
Q4 FY2018Dec 31, 2018-$5.93M–
Q3 FY2018Sep 30, 2018-$4.96M–
Q2 FY2018Jun 30, 2018-$4.38M–
Q1 FY2018Mar 31, 2018-$3.14M–

More Trevi Therapeutics figures

See a number that looks wrong?